ORPH Key Statistics, Chart & Performance
The current stock price of ORPH is 0.87 null. In the past month the price decreased by -28.1%. In the past year, price decreased by -89.88%.
ORPH Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.29 | 388.96B | ||
| AMGN | AMGEN INC | 14.91 | 175.60B | ||
| GILD | GILEAD SCIENCES INC | 14.79 | 150.25B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.72 | 117.69B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.7 | 83.72B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 780.96 | 52.62B | ||
| INSM | INSMED INC | N/A | 37.53B | ||
| NTRA | NATERA INC | N/A | 32.34B | ||
| BIIB | BIOGEN INC | 11.21 | 27.52B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.31 | 20.81B | ||
| INCY | INCYTE CORP | 16.65 | 20.98B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 22.94B |
Related stock screener links
About ORPH
Company Profile
Orphazyme A/S is a biopharmaceutical company, which engages in the development of treatment for patients living with life-threatening and debilitating rare diseases. The company develops new therapies for the treatment of a family of genetic disorders. The firm's main focus is on preclinical development of medicines for the treatment of lysosomal storage diseases (LSDs), a group of approximately 50 genetic disorders that result from deficiencies of lysosomal enzymes or other lysosomal components, and protein aggregation diseases. The Company’s candidate, arimoclomol, stimulates the production of the cells’ protein rescue system, the heat shock proteins, which helps the misfolded proteins to either get back to their functional shape or, if this cannot be achieved, remove them from the cells by means of the cells’ recycling system, the lysosomes, so they no longer form toxic aggregates. The firm collaborates with academic institutions in Europe and the United States.
Company Info
ORPHAZYME A/S - ADR
Ole Maaloees Vej 3, Copenhagen N
KOEBENHAVN DK-2200 DK
CEO: Anders Vadsholt
Employees: 180
Phone: 4539178272.0
ORPHAZYME A/S - ADR / ORPH FAQ
Can you describe the business of ORPHAZYME A/S - ADR?
Orphazyme A/S is a biopharmaceutical company, which engages in the development of treatment for patients living with life-threatening and debilitating rare diseases. The company develops new therapies for the treatment of a family of genetic disorders. The firm's main focus is on preclinical development of medicines for the treatment of lysosomal storage diseases (LSDs), a group of approximately 50 genetic disorders that result from deficiencies of lysosomal enzymes or other lysosomal components, and protein aggregation diseases. The Company’s candidate, arimoclomol, stimulates the production of the cells’ protein rescue system, the heat shock proteins, which helps the misfolded proteins to either get back to their functional shape or, if this cannot be achieved, remove them from the cells by means of the cells’ recycling system, the lysosomes, so they no longer form toxic aggregates. The firm collaborates with academic institutions in Europe and the United States.
Can you provide the latest stock price for ORPHAZYME A/S - ADR?
The current stock price of ORPH is 0.87 null. The price decreased by -2.25% in the last trading session.
What is the dividend status of ORPHAZYME A/S - ADR?
ORPH does not pay a dividend.
What is the ChartMill technical and fundamental rating of ORPH stock?
ORPH has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
Where is ORPHAZYME A/S - ADR (ORPH) stock traded?
ORPH stock is listed on the Nasdaq exchange.
What sector and industry does ORPHAZYME A/S - ADR belong to?
ORPHAZYME A/S - ADR (ORPH) operates in the Health Care sector and the Biotechnology industry.
ORPH Technical Analysis
ORPH Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to ORPH. Both the profitability and financial health of ORPH have multiple concerns.
ORPH Financial Highlights
Over the last trailing twelve months ORPH reported a non-GAAP Earnings per Share(EPS) of -3.79. The EPS decreased by -37.51% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | -6429.52% | ||
| ROA | -197.56% | ||
| ROE | N/A | ||
| Debt/Equity | 0.14 |
ORPH Forecast & Estimates
9 analysts have analysed ORPH and the average price target is 15.81 null. This implies a price increase of 1717.72% is expected in the next year compared to the current price of 0.87.